1-Molar gadobutrol as a contrast agent for computed tomography: Results from a comparative porcine study

Investigative Radiology

Volumn 38, Issue 4, 2003, Pages 193-199

  Kalinowski, Marc ^a   Kress, Oliver ^a   Wels, Thomas ^b   Alfke, H ^a   Klose, Klaus Jochen ^a   Wagner, Hans Joachim ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Computed tomography; Contrast agents; Experimental studies

Indexed keywords

GADOBUTROL; IODINATED CONTRAST MEDIUM; IOPROMIDE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DENSITY; DRUG EFFICACY; KINETICS; MALE; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; SWINE;

EID: 0037382291     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200304000-00002     Document Type: Article

References (34)

1. Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and non-ionic contrast media. A report from the Japanese Committee on the safety of contrast media. Radiology 1990;175:621-628.
2. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995;47:254-261.
3. Porter GA. Radiocontrast-induced nephropathy. Nephrol Dial Transplant 1994;9:146-56.
4. Tepel G, Van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
5. Cardinal HN, Holdsworth DW, Drangova M, et al. Experimental and theoretical x-ray imaging performance comparison of iodine and lanthanide contrast agents. Med Phys 1993;20:15-31.
6. Schild HH, Weber W, Boeck E, et al. Gadolinium-DTPA (Magnevist) as contrast medium for arterial DSA [article in German]. Fortschr Röntgenstr 1994;160:218-221.
7. Kaufman JA, Geller SC, Waltman AC. Renal insufficiency: gadopentetate dimeglumine as a radiographic contrast agent during peripheral vascular interventional procedures. Radiology 1996;198:579-581.
8. Matchett WJ, McFarland DR, Russell DK, et al. Azotemia: gadopentetate dimeglumine as contrast agent at digital subtraction angiography. Radiology 1996;201:569-571.
9. Fobbe F, Wacker F, Wagner S. Arterial angiography in high-kilovoltage technique with gadolinium as the contrast agent: first clinical experience. Eur Radiol 1996;6:224-229.
10. Spinosa DJ, Matsumoto AH, Angle JF, et al. Use of gadopentetate dimeglumine as a contrast agent for percutaneous transluminal renal angioplasty and stent placement. Kidney Int 1998;53:503-507.
11. Hammer FD, Goffette PP, Malaise J, et al. Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. Eur Radiology 1999;9:128-136.
12. Kinno Y, Odagiri K, Andoh K, et al. Gadopentetate dimeglumine as an alternative contrast material for use in angiography. AJR 1993;160:1293-1294.
13. M. Kalinowski, O. Kress, T. Wels, et al. x-ray digital subtraction angiography with 1 M gadobutrol: results from a comparative porcine study with iodinated contrast agents. Invest Radiol 2002;37:254-262.
14. Bloem JL, Wondergreen J. Gd-DTPA as a contrast agent in CT. Radiology 1989;171:578-579.
15. Quinn AD, O'Hare NJ, Wallis FJ, et al. Gd-DTPA: an alternative contrast medium for CT. J Comput Assist Tomogr 1994;18:634-636.
16. Schmitz SA, Wagner S, Schumann-Giampieri G, et al. Evaluation of gadobutrol in a rabbit model as a new lanthanide contrast agent for computed tomography. Invest Radiol 1995;30:644-649.
17. Tombach B, Heindel W. Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 2002;12:1550-1556.
18. Fink C, Bock M, Kiessling F, et al. Interstitial magnetic resonance lymphography with gadobutrol in rats: evaluation of contrast kinetics. Invest Radiol 2002;37:656-662.
19. Haage P, Karaagac S, Adam G, et al. Gadolinium containing contrast agents for pulmonary ventilation magnetic resonance imaging: preliminary results. Invest Radiol 2002;37:120-125.
20. O'Hare NJ. Contrast agent CT imaging in variable sized organs using single energy synchroton radiation. Phys Med Biol 1992;37:1519-1530.
21. Gierada DS, Bae KT. Gadolinium as CT contrast agent: assessment in a porcine model. Radiology 1999;210:829-834.
22. Bae KT, Heiken JT, Brink JA. Effect of contrast injection rate on peak aortic and hepatic enhancement at CT-pharmacokinetic analysis and experimental porcine model. Radiology 1998;206:455-464.
23. Foley WD, Hoffmann RG, Quiroz FA, et al. Hepatic helical CT: contrast material injection protocol. Radiology 1994;192:367-371.
24. Freeny PC, Gardner JC, von Ingersleben G, et al. Hepatic helical CT: effect of reduction of iodine dose of intravenous contrast material on hepatic contrast enhancement. Radiology 1995;197:89-93.
25. Vogler H, Platzek J, Schuhmann-Giampieri G, et al. Preclinical evaluation of gadobutrol: a new extracellular contrast agent for magnetic resonance imaging. Eur Radiology 1995;21:1-10.
26. Staks T, Schumann-Giampieri G, Frenzel T, et al. Pharmacokinetics, dose-proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 1994;29:709-715.
27. Haustein J, Niendorf HP, Krestin G, et al. Renal tolerance of gadolinium-DTPA/dinieglumine in patients with chronic renal failure. Invest Radiol 1992;27:153-156.
28. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502.
29. Tombach P, Bremer C, Reimer P, et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol 2000;35:35-40.
30. Goldstein H, Kashanian F, Blumetti R, et al. Safety assessment of gadopentetate dimeglumine in US clinical trials. Radiology 1990;174:17-34.
31. Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 1996;6:162-166.
32. Niendorf HP, Haustein J, Louton T, et al. Safety and tolerance after intravenous administration of 0.3mmol/kg Gd-DTPA: results from a randomized controlled clinical trial. Invest Radiol 1991;26:221-223.
33. Nyman U, Elmstahl B, Leander P, et al. Are gadolinium-based contrast media really safer than iodinated contrast media for digital subtraction angiography in patients with azotemia? Radiology 2002;223:311-318.
34. Ruth C, Joseph PM. A comparison of beam hardening artifacts in x-ray computerized tomography with gadolinium and iodine contrast agents. Med Phys 1995;22:1977-1982.